BioCentury This Week

• Ep. 280 - China Competition. Plus: FDA Firings and Biotech IPOs

  Rather than fretting over increasing competition from Chinese life sciences companies, biotechs in the U.S. should rise to the challenge and learn from their competitors. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the increasing pace of innovation from China and how U.S. biotechs need to meet the moment, delivering key takeaways from Editor in Chief Simone Fishburn’s fireside chat with industry leader John Maraganore at the BIO CEO & Investor Forum in New York last week. The team also discusses the fallout from staffing cuts at FDA — severely damaged morale among remaining staff and the potential for a higher approval bar, among others — leadership at the agency and the state of biotech IPOs on NASDAQ and in Korea.View full story: https://www.biocentury.com/article/65511200:00 - Introduction00:58 - Competing with China14:13 - FDA, NIH Staff Cuts20:16 - Biotech IPOs To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text

  --------  

  27:52
• Ep. 279 - East-West Summit Preview

  Western VCs are paying more attention than ever to innovation emerging from Asia — from antibody-drug conjugates to bispecifics, AI and beyond — as the NewCo Model becomes the latest trend to bridge talent, assets and venture money across the Pacific and on to North America and Europe. On a special edition of BioCentury This Week podcast, a trio of leaders from Asia’s life sciences ecosystem — Khoo Shih of Singaporean investor ClavystBio, McKinsey & Company’s Anirudh Roy Popli and Wendy Pan of Goodwin and BayHelix — join the BioCentury team to set the stage for the fourth BioCentury-BayHelix East-West Biopharma Summit. They discuss the innovations driving the deal flow from East to West, including the creation of start-ups in the West formed around assets from Asia. The summit takes place March 3-5 in Singapore.View full story: https://www.biocentury.com/article/65510800:00 - Introduction04:49 - The Newco Model and Industry Trends09:13 - BayHelix and Cross-Border Transactions11:31 - McKinsey's Perspective on Asian Innovation26:58 - Final Thoughts and Registration InformationTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text

  --------  

  29:54
• Ep. 278 - Trump 2.0’s Impact on FDA, NIH. Plus: Precision Medicine

  White House plans to slash FDA and NIH risk decimating two agencies at the core of U.S. biomedical innovation. On the latest BioCentury This Week podcast, BioCentury’s editors assess draft plans by the Trump administration that seek to halve FDA staff, cut NIH, and reduce overhead payments to academic institutions. The policy addressed in a recent Guest Commentary for BioCentury, “Defending the NIH, the NSF and the foundation of American science,” by the Scleroderma Research Foundation’s Luke Evnin, Peter Rubin of No Patient Left Behind, and Ra Capital’s Peter Kolchinsky.BioCentury’s team also discusses how biotechs are becoming increasingly successful at navigating the obstacles to get precision therapies across the FDA finish line.View full story: https://www.biocentury.com/article/65503400:00 - Introduction00:59 - FDA, NIH & Trump 2.016:26 - Biotechs & Precision MedicineTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text

  --------  

  26:14
• Ep. 277 - Asia's NewCo Model, FDA Tipping Point, Vertex's Pain Drug

  The boom in the creation of companies that were launched in the West based on assets sourced in Asia signals China’s galloping speed of innovation. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the “NewCo Model,” who the players are, from CEOs and companies to investors; the areas of innovation the start-ups are tackling; and the evolution of the trend. (Read about the company that kicked off the trend, Arrivent, here.)The editors also assess how personnel losses at FDA from the Trump administration’s plans to slash government payrolls are likely to cause short- and long-term harm for the agency and the drug approval process. And a new pain therapy from Vertex is in the spotlight as the CF specialist enters new turf.View full story: https://www.biocentury.com/article/65494600:00 - Introduction01:20 - Asia's NewCo Model16:22 - FDA Tipping Point20:27 - Vertex's Pain DrugTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text

  --------  

  25:03
• Ep. 276 - Precision Neuropsychiatry Spotlight With ICON's Peter Schueler

  Psychiatric drug development has had major wins over the past year-and-a-half — think Karuna Pharmaceuticals' $14 billion takeout by Bristol Myers Squibb and the subsequent launch of a new schizophrenia therapy — but targeted neuropsychiatric drug development is still in its infancy. On a special edition of the BioCentury This Week podcast, BioCentury’s editors detail the promise of precision medicine in the space and break down what recent setbacks for key players mean for next steps in the clinic. The team is joined by special guest Peter Schueler, SVP of drug development solutions, neurosciences, at ICON, who delivers takeaways from this month’s the ECNP Roadmap Meeting on Precision Psychiatry in Frankfurt and a recent white paper by ICON. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/654903 00:01 - Sponsor Message: ICON Biotech02:20 - Precision Neuropsychiatry06:39 - Insights from ICON's Peter Schueler15:59 - Challenges in NeuropsychTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text

  --------  

  21:07

Más podcasts de Ciencias

Podcasts a la moda de Ciencias

Acerca de BioCentury This Week